Agenda for Day Two - Wednesday April 28, 2027Wednesday, 28 April 2027 - ET (Eastern Time, GMT-05:00)

• How the Fraud Division's creation and the realignment of personnel and FDCA expertise is reshaping enforcement priorities for life sciences
• What the Department's new posture on corporate enforcement, whistleblowers, and self-disclosure signals for compliance programs going forward
• A look at where policy is headed next, and what pharmaceutical compliance leaders should be watching

The decisions landing on today’s General Counsel increasingly extends beyond strictly legal questions, requiring judgement across compliance, enforcement exposures, business strategy, and enterprise risk.

• Navigate high-stakes decisions when legal, compliance, and business priorities collide
• Shape how GC, CCO, executive leadership, and board align around emerging risks and critical decisions
• Draw the line between acceptable business risk and which the organization cannot afford to take

For many compliance professionals, the reporting structure debate is over. The real challenge is building an effective partnership with legal. Join General Counsel and Compliance leaders for a candid discussion on how to align priorities, build influence, and work together when the stakes are highest

• Navigate the risks and benefits of reporting into legal, from privilege considerations to organizational influence
• Build credibility and trust with General Counsel while demonstrating compliance's strategic value
• Define the partnership during investigations, high-risk decisions, and moments that test alignment
• Explore successful GC-compliance partnerships and the lessons they offer for stronger collaboration and business impact

FCPA enforcement didn’t just resume in 2026, it came back with a shaper, narrower focus that changes where the real exposure sits

• Decode DOJ's new FCPA enforcement priorities, including emerging cartel-nexus theory affecting companies with manufacturing or supply chain exposure in high-risk regions
• Navigate China's new anti-corruption and anti-monopoly guidelines and their impact on pharmaceutical and device companies operating there
• Designing a core compliance program that flexes across increasingly divergent regional requirements

OIG has made some of its most significant changes to Corporate Integrity Agreements in over a decade, and the new terms go well beyond the basics.

• Identify what's new in CIA terms including:board accountability, compliance officer independence, AI governance, and more
• Understandhow the terms shape day-to-day compliance operations over the life of an agreement
• Buildmonitoring and reporting structures that would hold up even without a CIA in place

Fraud detection used to start with a tip. Increasingly it starts with a pattern in the data

• Understanding what's driving analytics-first fraud detection
• Examining the data behind the trend
• Learning how organizations deploy analytics in investigations and where tools succeed or fail

Outside counsel is advising clients differently than they were a year ago, shaped by everything from state enforcement activity to shifting FCPA priorities

• Track how legal advice on structuring patient support, speaker and pricing programs has shifted in response to recent enforcement activity
• Pinpoint where practice chairs tell clients to be more conservative and where they see more flexibility than expected
• Reveal what questions practice chairs are getting asked more often by in-house counsel and compliance right now

• Connect insights across due diligence, monitoring, audits and investigations to identify emerging risks
• Break down silos to build a more complete view of risk across the enterprise
• Leverage smarter processes, data and technology to turn risk information into actionable intelligence

• Identify where PBM rebate and fee arrangements now carry anti-kickback exposures
• Examine what new transparency requirements mean for PBM agreement structure
• Define how compliance should vet and monitor PBM relationships as third-party risks

Panel (25 minutes)

• Identify where regulatory and compliance exposure is emerging across market access
• Examine how compliance and market access teams are restructuring how they work together
• Share practical mitigation strategies that protect the organization without unnecessarily slowing the business

Community Conversation (30 Minutes)

Join a guided discussion to compare how peers are navigating market access risk, cross-functional responsibilities, and emerging gray areas.